Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-02T19:40:55.520Z.
Calculation as of: 2026-10-02T19:40:55.520Z.
Quote observation: 2026-10-02T19:40:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a42e17afc1a1b5c0c05c4bcc318afc1e85bdb01f5d7a677422ba224d703768eb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Recursion Pharmaceuticals, Inc.
Market Cap
$2.14B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.73B
EV/EBIT Ratio
8.92x
TTM Avg
17.02x
3Y Avg
17.02x
5Y Avg
19.12x
Market Cap
$2.74B
EV/EBIT Ratio
38.39x
TTM Avg
47.18x
3Y Avg
64.57x
5Y Avg
64.57x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.14B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.51B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 8.92x | 17.02x | 17.02x | 19.12x |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 38.39x | 47.18x | 64.57x | 64.57x |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | N/A | 64.08x | 60.43x | 132.37x |
| NRC Health (NRC)vs › | $459.30M | 37.05x | 22.61x | 18.66x | 19.84x |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
